JPWO2023172890A5 - - Google Patents
Info
- Publication number
- JPWO2023172890A5 JPWO2023172890A5 JP2024553452A JP2024553452A JPWO2023172890A5 JP WO2023172890 A5 JPWO2023172890 A5 JP WO2023172890A5 JP 2024553452 A JP2024553452 A JP 2024553452A JP 2024553452 A JP2024553452 A JP 2024553452A JP WO2023172890 A5 JPWO2023172890 A5 JP WO2023172890A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- amino acid
- constant region
- chain constant
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268945P | 2022-03-07 | 2022-03-07 | |
| US63/268,945 | 2022-03-07 | ||
| PCT/US2023/063821 WO2023172890A2 (en) | 2022-03-07 | 2023-03-07 | Anti-ilt2 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508075A JP2025508075A (ja) | 2025-03-21 |
| JPWO2023172890A5 true JPWO2023172890A5 (https=) | 2026-03-12 |
| JP2025508075A5 JP2025508075A5 (https=) | 2026-03-12 |
Family
ID=87935886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553452A Pending JP2025508075A (ja) | 2022-03-07 | 2023-03-07 | 抗ｉｌｔ２抗体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250109201A1 (https=) |
| EP (1) | EP4490196A2 (https=) |
| JP (1) | JP2025508075A (https=) |
| KR (1) | KR20250004950A (https=) |
| CN (1) | CN119365487A (https=) |
| AU (1) | AU2023231622A1 (https=) |
| CA (1) | CA3254318A1 (https=) |
| IL (1) | IL315487A (https=) |
| MX (1) | MX2024010982A (https=) |
| WO (1) | WO2023172890A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025059304A2 (en) * | 2023-09-12 | 2025-03-20 | Agenus Inc. | Methods of treating cancer using ilt2 antibodies and combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2541360A1 (en) * | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| EP3580239A4 (en) * | 2017-02-09 | 2021-07-28 | Bluefin Biomedicine, Inc. | ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES |
| MX2021015024A (es) * | 2020-04-28 | 2022-01-18 | Univ Rockefeller | Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos. |
| AU2021265801B2 (en) * | 2020-05-01 | 2026-04-02 | Ngm Biopharmaceuticals, Inc. | ILT-binding agents and methods of use thereof |
-
2023
- 2023-03-07 AU AU2023231622A patent/AU2023231622A1/en active Pending
- 2023-03-07 EP EP23767599.6A patent/EP4490196A2/en active Pending
- 2023-03-07 WO PCT/US2023/063821 patent/WO2023172890A2/en not_active Ceased
- 2023-03-07 CA CA3254318A patent/CA3254318A1/en active Pending
- 2023-03-07 CN CN202380038440.3A patent/CN119365487A/zh active Pending
- 2023-03-07 KR KR1020247032336A patent/KR20250004950A/ko active Pending
- 2023-03-07 IL IL315487A patent/IL315487A/en unknown
- 2023-03-07 JP JP2024553452A patent/JP2025508075A/ja active Pending
-
2024
- 2024-09-06 US US18/827,368 patent/US20250109201A1/en active Pending
- 2024-09-06 MX MX2024010982A patent/MX2024010982A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331119B2 (en) | Modified Fc fragment, antibody comprising same, and application thereof | |
| AU2016274485B2 (en) | LAG-3-binding molecules and methods of use thereof | |
| KR102761886B1 (ko) | Pd-1-결합 분자 및 그것의 사용 방법 | |
| JP2021525082A5 (https=) | ||
| JP2018035138A5 (https=) | ||
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| TWI814715B (zh) | Ａｄａｍ９結合分子及使用其的方法 | |
| US20230174648A1 (en) | Sirp alpha and sirp beta 1 antibodies and uses thereof | |
| EP3880707A1 (en) | HUMANIZED ANTI-SIRPa ANTIBODIES | |
| JP2021534797A5 (https=) | ||
| JP2025186381A (ja) | Ｃｄ１３７結合分子及びその使用 | |
| CA3226306A1 (en) | Novel multi-specific molecules | |
| JPWO2020185722A5 (https=) | ||
| JPWO2023172890A5 (https=) | ||
| JPWO2020047374A5 (https=) | ||
| JPWO2021213475A5 (https=) | ||
| JPWO2021042019A5 (https=) | ||
| JP7192042B2 (ja) | Ｌａｇ‐３結合分子及びその使用方法 | |
| JPWO2019236965A5 (https=) | ||
| JPWO2021216956A5 (https=) | ||
| NZ769634A (en) | Anti-sirpa antibodies and methods of use thereof | |
| RU2023123926A (ru) | Антитела к vista и их применение | |
| NZ769634B2 (en) | Anti-sirpa antibodies and methods of use thereof | |
| NZ775277B2 (en) | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof | |
| JPWO2022188652A5 (https=) |